Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis

(2540) Views  (789) Full article downloads

Authors: Joseph R Ferencz, Eli Rosen, Guy Tam, Gila Gilady, Alexander Rubowich, et al

Published Date May 2007 Volume 2007:1(3) Pages 347 - 351

DOI: http://dx.doi.org/10.2147/OPTH.S

Joseph R Ferencz¹, Eli Rosen¹, Guy Tam¹, Gila Gilady¹, Alexander Rubowich¹, Ehud I Assia¹, Ze’ev Korzets²

¹Department of Ophthalmology and ²Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel; ^1,2Sackler Medical School, Tel Aviv University, Tel Aviv, Israel

Objective: To report on the use of intravitreal bevacizumab (an anti-vascular endothelial growth factor [VEGF] monoclonal antibody) as treatment of diffuse exudative retinal detachment due to ischemic central retinal vein occlusion (CRVO).

Design: Interventional case report.

Patient: A 27-year old woman on peritoneal dialysis because of end stage renal failure (ESRF) due to perinuclear antineutrophil cytoplasmic antibody (p-ANCA) associated vasculitis presented with acute unilateral blurred vision. Visual acuity (VA) rapidly deteriorated. Examination revealed the development of total bullous exudative retinal detachment following ischemic CRVO.

Intervention: Two intravitreal injections of bevacizumab (2.5 mg/0.1ml) were administered followed by panretinal laser photocoagulation.

Main outcome measures: VA, retinal detachment, and changes in macular edema.

Results: Prompt significant resolution of exudative retinal detachment with a corresponding gradual improvement of VA from light perception to finger counting. At follow-up examination after 8-months, the retina remained attached.

Conclusion: Intravitreal bevacizumab proved to be a useful treatment modality in diffuse exudative retinal detachment due to CRVO.

Keywords: bevacizumab, CRVO, exudative retinal detachment, p-ANCA vasculitis